Not Specified (Autoimmune Focus)
Autoimmune Disease
Pre-clinicalActive
Key Facts
About Narwhal Bio
Narwhal Bio is an early-stage biotech leveraging advanced cell engineering to develop therapies for oncology and immunology. The company is building a platform to create more precise and effective engineered immune cells, targeting significant unmet needs in cancer and autoimmune conditions. As a private, pre-clinical entity, it is positioned in the competitive but high-potential cell therapy space. Its success will depend on translating its platform technology into clinically validated treatments.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Fusion Immunotherapeutic | HCW Biologics | Clinical Trial |
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Undisclosed Precision Biologic | Rhapsogen | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| GIM-407 | Georgiamune | Preclinical |
| Autoimmunity Program | Accipiter Biosciences | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Appus | BioVectis | Pre-clinical |
| Leap 1121 | Ability Biotherapeutics | Preclinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |